Please login to the form below
biologic
This page shows the latest biologic news and features for those working in and with pharma, biotech and healthcare.
CanSinoBIO considers booster jab for COVID-19 vaccine
The efficacy of Chinese biotech company CanSino Biologics's (CanSinoBio) single-dose COVID-19 vaccine could decrease over time, according to the company’s chief scientific officer Zhu Tao.
Latest news
-
Lilly reports positive data from its phase 3 ulcerative colitis trial
Mirikizumab also reduced symptoms in patients who had previously not responded to or stopped responding to biologic and/or Janus Kinase (JAK) inhibitor drugs.
-
AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population
In a statement, AZ said that tezepelumab is the first and only biologic medicine to consistently and significantly reduce AAER in a broad population of severe asthma patients, irrespective of baseline ... The unprecedented results from the NAVIGATOR
-
FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
the FDA’s Center for Biologics Evaluation and Research.
-
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition
Viela Bio spun out of AstraZeneca’s Medimmune biologics unit in 2018 with six molecules and $250m in funding from a number of investors. ... Adding Viela’s research and clinical development capabilities along with its deep, mid-stage biologics
-
Lilly partners with Merus on development of bispecific antibodies for cancer
We expect these therapies will become an important component of the Loxo Oncology at Lilly biologics strategy," said Jacob Van Naarden, chief operating officer of Loxo Oncology at Lilly.
More from news
Approximately 21 fully matching, plus 600 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
Other safety and manufacturing events such as three patient deaths in the high-dose arm of the Audentes’ ASPIRO trial and an FDA refusal to review the biologics licence application for
-
Growing evidence supports the important role of biosimilars in healthcare
In 2019, four of the top five prescription expenditures in the US were biologics and accounted for approximately $46 billion in expenditures. ... An estimated 1.2 million US patients could gain access to biologics by 2025 as the result of increasing
-
The US celebrates five years of biosimilars on the market – a look to the past, present and future
In comparison to many small-molecule medicines, biologics are often challenging to develop and costly to produce. ... patient access to more affordable, high-quality, and potentially life- changing biologic treatments.
-
Exploring the potential of eosinophils
Peter Howarth (pictured above), Global Clinical Scientific Lead for Biologics at GSK looks at the emerging science behind eosinophils and how it is helping to guide the company’s research and ... decisions. The eosinophils test is now well-established
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
in the manufacturing of complex biologic therapies, Amgen is leveraging this expertise to meet this growing need.
More from intelligence
Approximately 5 fully matching, plus 87 partially matching documents found.
Latest appointments
-
Ex-BMS exec jumps to Gilead to lead research group
That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.
-
New hires at Crescendo, Healx and Galecto
The latest movers in pharma. Crescendo. Crescendo Biologics has appointed Kenji Hashimoto as its new chief medical officer, who joins Crescendo with over 15 years of experience in oncology and ... Kenji has considerable immuno-oncology expertise and an
-
New hires at FibroGen, Saniona and Turbine
Tuna currently serves as chief scientific officer at Adaptate Biotherapeutics, and has over 15 years of experience in biologics drug discovery and development.
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Bahija has more than 25 years of international leadership experience within the pharmaceutical industry, and joins Immunocore from AstraZeneca, where she has served as President of MedImmune, its global biologics research ... A champion for science and
-
BMS appoints new commercial leader, Davies joins Eisai and more
Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space.
More from appointments
Approximately 8 fully matching, plus 48 partially matching documents found.
Latest from PMHub
-
Live Webinar: When Wireless Technology Meets Drug Delivery
Fireside Chat with Robert Niichel, Founder and CEO at SmartTab. Founder/CEO of SmartTab, will sit down with Natalie Yeadon to explore the concept of personalized wireless drug delivery, including its advantages, barriers, and current status.
-
Integrated NHS finances: what do they mean for High Cost Drugs?
So, those with High Cost biologics are going to have to think carefully about their value proposition.
-
Living with psoriasis: a patient perspective
million[i]) received a biologic therapy in the UK in 2012.
-
Covid-19: how is it affecting prescribing patterns?
because as generic biologics get approved, use of branded biologics goes down and the arthritis pathway becomes cheaper to run. ... Yet, Gilenya aside, we found the medications trending upward were orally administered, which demonstrates a market
-
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen. ... Biobetters are enhanced versions of originator biologics, which potentially offer added value to
More from PMHub
Approximately 8 fully matching, plus 41 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
-
Principal Medical Writer
-
Varies on experience
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
- Moderna launches COVID-19 vaccine booster study to address new variants
- WHITE PAPER: Why do men die younger?
- Opdivo improves survival in oesophageal cancer
- Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients
- UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- WHITE PAPER: Why do men die younger?
- It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
- 3 tips to show patient diversity in your clinical trial materials
- Here are some useful tips to help get your hands on authentically diverse stock photos....
- Virtual congresses: video thrilled the cardio tsar
- Chris Ross explores the key learnings from a year of virtual congresses...
Quick links
Infographics
